E1-F.Buruk, U. Berberoğlu, I.Pak, E.Aksaz ,O.Çelen. Gastric cancer and Helicobacterpylori infection.British Journal of Surgery1993;80:378-379.

• Lima VP, Silva-Fernandes IJL, Alves MKS, et al. Prevalence ofHelicobacter pylorigenotypes (vacA,cagA,cagE andvirB11) in gastric cancer in Brazilian’s patients: An association with histopathological parameters.Cancer Epidemiology2011; 35: 32-37.

• VP Lima, MAP Lima, MVP Ferreira, MAP Barros .The relationship betweenHelicobacter pylorigenescagE andvirB11 and gastric cancer.J. Infectious Disease2010;14(7):613-617

• Lima VP, de Lima MAP, Andre AR, e al.H pylori (CagA) and Epstein-Barr virus infection in gastric carcinomas: Correlation with p53 mutation and c-Myc, Bcl-2 and Bax expression. World Journal of Gastroenterology 2008;14(6):884-891

• Rocco A, Nardone G.Diet, H pylori infection and gastric cancer: Evidence and controversies. World Journal of Gastroenterology 2007;13(21):2901-2912.

• Hamaguchi K, Ogawa K, Katsube T, Konno S, Aiba M. Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residuel stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the residuel stomach before and after Helicobacter pylori eradication.Langenbecks Archives of Surgery2004;389:83-91.

• Atalay C, Atalay G, Altınok M. Serum Helicobacter pylori IgG and IgA levels in patients with gastric cancer.Neoplasma2003;50:185-190.

• Cho HJ, Kim JY, Yoo J, Lee SS. Gastric carcinoma with lymphoid stroma- Incidence of EBV and Helicobacter pylori infection. AppliedImmunohistochemistry & Molecular Morpho2003;11:149-152.

• Kyrlagkitsis I, Karamanolis DG. Premalignant lesions and conditions for gastric adenocarcinoma: Diagnosis, management and surveillance guidelines.Hepato-Gastroenterology2003;50:592-600.

• Katsube T, Ogawa K, Hamaguchi K, Murayama M, Konnno S, Shimakawa T, Naritaka Y, Yagawa H, Kajiwara T, Aiba M. Prevalence of Helicobacter pylori in the residual stomach after gastrectomy for gastric cancer.Hepato-Gastroenterology2002;49:128-132.

• Kath R, Fiehler J, Schneider CP, Hoffken K. Gastric cancer in very young adults: apropos four patients and a review of the literature.Journal of Cancer Research and Clinical Oncology2000;126:233-237.

• Ashley SW, Evoy D, Daly JM. Stomach In: Schwartz SI, ed.Principles of Surgery 7^thed. McGraw Hill; 1999:1181-1215.

• Jonkers D, Houben P, Hameeteman W, Stobberingh E, de Bruine A, Arends JW, Biemond I, Lundqvist G, Stockbrugger R. Differential features of gastric cancer patients, either Helicobacter pylori positive or Helicobacter pylori negative.Italian Journal of Gastroenterology and Hepatology1999;31:836-841.

• Tabata H, Fuchigami T, Kobayashi H, Sakai Y, Nakanishi M, Tomioka K, Nakamura S, Fujishima M. Helicobacter pylori and mucosal atrophy in patients with gastric cancer – A special study regarding the methods for detecting Helicobacter pylori.Digestive Diseases and Sciences1999;44:2027-2034.

• Eslick GD, Lim LLY, Byles JE, Xia HHX, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: A meta-analysis.American Journal of Gastroenterology1999;94:2373-2379.

• Nyren O. Is Helicobacter pylori really the cause of gastric cancer?Seminars In Cancer Biology1998;8:275-283.

• Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in Mongolian Gerbils.Gastroenterology1998;115:642-648.

• Enomoto H, Watanabe H, Nishikura K, Umezawa H, Asakura H. Topographic distribution of Helicobacter pylori in the resected stomach.European Journal of Gastroenterology & Hepatology1998;10:473-478.

• Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer.Gastroenterology1998;114:1169-1179.

• Borch K, Sjostedt C, Hannestad U, Soderholm JD, Franzen L, Mardh S.Asymptomatic Helicobacter pylori gastritis is associated with increased sucrose permeability.Digestive Diseases and Sciences1998;43:749-753.

• Iseki K, Tatsuta M, Iishi H, Baba M, Ishiguro S. Helicobacter pylori infection in patients with early gastric cancer by the endoscopic phenol red test.Gut1998;42:20-23.

• Wu MS, Yang KC, Shun CT, Hsiao TJ, Lin CC, Wang HP, Chuang SM, Lee WJ, Lin JT. Distinct clinicopathologic characteristics of diffuse- and intestinal-type gastric cancer in Taiwan.Journal of Clinical Gastroenterology1997;25:646-649.

• McFarlane GA, Munro A. Helicobacter pylori and gastric cancer.British Journal of Surgery1997;84:1190-1199.

• Wu MS, Chen SY, Shun CT, Lee WJ, Wang HP, Wang TH, Chen CJ, Lin JT. Increased prevalence of Helicobacter pylori infection among patients affected with intestinal-type gastric cancer at non-cardiac locations.Journal of Gastroenterology and Hepatology1997;12:425-428.

• MartindeArgila C, Boixeda D, Redondo C, Alvarez I, Gisbert JP, Plaza AG, Canton R. Relation between histologic subtypes and location of gastric cancer and Helicobacter pylori.Scandinavian Journal of Gastroenterology1997;32:303-307.

• Nagahata Y, Kawakita N, Azumi Y, Numata N, Yano M, Saitoh Y. Etiological involvement of Helicobacter pylori in ”reflux” gastritis after gastrectomy.American Journal of Gastroenterology1996;91:2130-2134.

• McGuigan JE. Helicobacter pylori: The versatile pathogen.Digestive Diseases1996;14:289-303.

• Kokkola A, Valle J, Haapiainen R, Sipponen P, Kivilaakso E, Puolakkainen P. Helicobacter pylori infection in young patients with gastric carcinoma.Scandinavian Journal of Gastroenterology1996;31:643-647.

• Wu CW, Wu TC, Chang YR, Tsay SH, Yin SJ, Lui WY, Peng FK, Chi CW. Helicobacter pylori infection in patients with gastric adenocarcinoma.Tumori1996;82:40-44.

• Hansson LE, Engstrand L, Nyren O, Lindgren A. Prevalence of helicobacter-pylori infection in subtypes of gastric-cancer.Gastroenterology1995;109:885-888.

• Hu PJ, Li YY, Zhou MH, Chen MH, Du GG, Huang BJ, Mitchell HM, Hazell SL. Helicobacter-pylori-associated with a high prevalence of duodenal-ulcer disease and a low-prevalence of gastric-cancer in a developing-nation.Gut1995;36:198-202.

• Klimpfinger M. Therapeutic relevance of the histological gastritis classification.Wiener Klinische Wochenschrift1994;106:550-555.

E2–O.Çelen, M.J.O’Brien, J.C.Melby, R.M.Beazley. Factors Influencing Outcome of Surgery for Primary Aldosteronism.Archives of Surgery1996;131:646-650.

• Fingeret AL, Lee JA. Adrenal Venous Sampling in Primary Hyperaldosteronism.Current Surgery Reports2014;2:238.

• Kim SH, Ahn JE, Hong CE, et al. Changes in the clinical manifestations of primary aldosteronism.The Korean Journal of Internal Medicine2014;29(2):217-225.

• Viola A, Tizzani D, Monticone S, et al.Diagnosis and treatment of unilateral forms of primary aldosteronism.Curr Hypertens Rev. 2013 May;9(2):156-65.

• Stowasser M,Gordon RD. The renaissance of primary aldosteronism: what has it taught us?Heart Lung Circ.2013 Jun;22(6):412-20.

• Weisbrod AB,Webb RC,Mathur A, Et al. Adrenal histologic findings show no difference in clinical presentation and outcome in primary hyperaldosteronism.Ann Surg Oncol.2013 Mar;20(3):753-8

• Uribarrena-Amezaga R, Ortego J, Fuentes J et al. Prognostic value of lymph node micrometastasis in patients with colorectal cancer in Dukes stages A and B (T1-T4, N0, M0).Revista Espanola de Enfermedades Digestivas : Organo Oficial de la Sociedad Espanola de Patologia Digestiva2010, 102(3):176-186.

• Uribarrena-Amezaga R, Ortego J, Fuentes J et al. Prognostic Value of Microvascular Density in Dukes A and B (T1–T4, N0, M0) Colorectal Carcinoma.Gastroenterology Research and Practice.2009; Article ID 679830, 7 pages, https://dx.doi.org/10.1155/2009/679830

• Mazza A, Armigliato M, Zamboni S, et al.Endocrine arterial hypertension: therapeutic approach in clinical practice. Minerva Endocrinologica 2008;33(4):297-312.

• Karagiannis A, Tziomalos K, Kakafika AI, et al.Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas
  Endocrine-Related Cancer  2008;15(3):693-700.

• Funder JW, Carey RM, Fardella C, et al.Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2008;93(9):3266-3281.

• Mourad JJ, Girerd X, Milliez P, et al.Urinary aldosterone-to-active-renin ratio: A useful tool for predicting resolution of hypertension after adrenalectomy in patients with aldosterone-producing adenomas. American Journal of Hypertension 2008;21(7):742-747.

• Walz MK, Gwosdz R, Levin SL, et al.Retroperitoneoscopic adrenalectomy in Conn’s syndrome caused by adrenal adenomas or nodular hyperplasia. World Journal of Surgery 2008;32(5):847-853.

• Rossi GP, Bolognesi M, Rizzoni D, et al.Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008;51(5).1366-1371.

• Zarnegar R, Young WF, Lee J, et al.The aldosteronoma resolution score – Predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Annals of Surgery 2008;247(3):511-518.

• Zarnegar R, Lee J, Brunaud L, et al.Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma. Surgery 2007;142(6):921-928.

• Gordon RD, Stowasser M.Primary aldosteronism: the case for screening
  Nature Clinical Practice Nephrology 2007;3(11):582-583.

• Lau JHG, Drake W, Matson M.The current role of venous sampling in the localization of endocrine diseaseCardiovascular and Interventional Radiology2007;30(4):555-570.

• Pang TC, Bambach C, Monaghan JC, et al.Outcomes of laparoscopic adrenalectomy for hyperladosteronismANZ Journal Of Surgery 2007;77(9):768-773.

• Novello M, Catena C, Nadalini E, et al.Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatmentJournal of Hypertension 2007;25(7):1443-1450.

• Catena C, Colussi G, Nadahni E, et al.Relationships of plasma renin levels with renal function in patients with primary aldosteronismClinical Journal of The American Society of Nephrology 2007;2(4)722-731.

• Vesin C, Chabre O, Mallion JM, et al.Diagnosis and post-operative evolution of patients operated for adrenal adenoma (Conn syndrome). A 12-years retrospective study. Archives Des Maladies Du Coeur Et Des Vaisseaux 2007;100(2)121-125.
• Young WF.Primary aldosteronism: renaissance of a syndromeClinical Endocrinology 2007;66(5):607-618.

• Gockel I, Heintz A, Polta M, et al.Long-term results of endoscopic adrenalectomy for Conn’ syndromeAmerican Surgeon 2007;73(2)174-180.

• Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004)Hypertension Research2006;29(Suppl. S):S1-+.

• Tan YY, Ogilvie JB, Triponez F, et al.Selective use of adrenal venous sampling in the lateralization of aldosterone-producing adenomas. World Journal of Surgery 2006;30(5):879-885.

• Nwariaku FE, Miller BS, Auchus R, et al.Primary hyperaldosteronism – Effect of adrenal vein sampling on surgical outcome. Archives of Surgery 2006;141(5)497-502.

• Mattsson C, Young WF.Primary aldosteronism: diagnostic and treatment strategies. Nature Clinical Practice Nephrology2006;2(4):198-208.

• Novitsky YW, Kercher KW, Rosen MJ, et al.Clinical outcomes of laparoscopic adrenelectomy for lateralizing nodular hyperplasia.Surgery2005;138(6):1009-1016.

• Lumachi F, Ermani M, Basso SMM, et al. Long-term results of adrenelectomy in patients with aldosterone-producing adenomas: Multivariate analysis of factors affecting unresolved hypertension and review of the literature.American Surgeon2005;71(10):864-869.

• Ogilvie JB, Duh GY. New approaches to the minimally invasive treatment of adrenal lesions.Cancer Journal2005;11(1):64-72.

• Meyer A, Brabant G, Behrend M. Long-term follow-up after adrenelectomy for primary aldosteronism.World Journal of Surgery2005;29(2):155-159.

• Stowasser M, Gordon RD. The aldosteron-renin ratioin screening for primary aldosteronism.Endocrinologist2004;14(5):267-276.

• Al Fehaily M, Duh GY. Clinical manifestation of aldesteronoma.Surgical Clinics of North America2004;84(3):887-.

• Stowasser M, Gordon RD. Primary aldosteronism- careful investigation is essential and rewarding.Molecular and Cellular Endocrinology2004;217(1-2):33-39.

• Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF. Extensive personal experience – increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.Journal of Clinical Endocrinology and Metabolism2004;89:1045-1050.

• Stowasser M, Gordon RD. Primary Aldosteronism.Best Practice & Research Clinical Endocrinology & Metabolism2003;17:591-605.

• Young WF. Primary aldosteronism- treatment options.Growth Hormone & IGF Research2003;13(Suppl.A):S102-S108.

• Stowasser M, Gordon RD. Primary aldosteronism: from genesis to genetics.Trends in Endocrinology an Metabolism2003;14:310-317.

• Sidhu S, Gicquel C, Bambach CP, Campbell P, Magarey C, Robinson BG, Delbridge LW. Clinical and molecular aspects of adrenocortical tumourigenesis.ANZ Journal of Surgery2003;73:727-738.

• Wheeler MH, Harris DA. Diagnosis and management of primary aldosteronism.World Journal of Surgery2003;27:627-631.

• Harris DA, Au-Yong I, Basnyat PS, Sadler GP, Wheeler MH. Review of surgical management of aldosterone secreting tumours of the adrenal cortex.European Journal of Surgical Oncology2003;29:467-474.

• Lumachi F, Marzola MC, Zucchetta P, Tregnaghi A, Cecchin D, Favia G, Bui F. Non-invasive adrenal imaging in primary aldosteronism. Sensitivity and positive predictive value of radiocholesterol scintigraphy, CT scan and MRI.Nuclear Medicine Communications2003;24:683-688.

• Young WF. Minireview: Primary aldosteronism – Changing concepts in diagnosis and treatment.Endocrinology2003;144:2208-2213.

• Meria P, Kempf BF, Hermieu JF, Plouin PF,Duclos JM. Laparoscopic management of primary hyperaldosteronism: Clinical experience with 212 cases.Journal of Urology2003;169(1):32-35.

• Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism.British Journal of Surgery2002;89:1587-1593.

• Fukudome Y, Fujii K, Arima H, Ohya Y, Tsuchihashi T, Abe I, Fujishima M. Discriminating factors for recurrent hypertension in patients with primary aldosteronism after adrenalectomy.Hypertension Research2002;25:11-18.

• Rossi H, Kim A, Prinz RA. Primary hyperaldosteronism in the era of laparoscopic adrenalectomy.American Surgeon2002;68:253-256.

• Brand M, Dehmel B, Cristow S, Kettritz R. A strange case of hypokalaemia.Nephrology Dialysis Transplantation2002;17:297-299.

• Brunt LM, Moley JF, Doherty DM, Lairmore TC, DeBenedetti MK, Quasebarth MA. Outcomes analysis in patients undergoing laparoscopic adrenalectomy for hormonally active adrenal tumors.Surgery2001;130:629-634.

• Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, van Heerden JA. Primary aldosteronism: Factors associated with normalization of blood pressure after surgery.Annals of Internal Medicine2001;135:258-261.

• Horita Y, Inenaga T, Nakahama H, Ishibashi-Ueda H, Kawano Y, Nakamura S, Horio T, Okuda N, Ando M, Takishita S. Cause of residual hypertension after adrenalectomy in patients with primary aldosteronism.American Journal of Kidney Diseases2001;37:884-889.

• Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism.Journal of Hypertension2001;19:353-361.

• Nocaudie-Calzada M, Huglo D, Lambert M, Ernst O, Proye C, Werneau JL, Marchandise X. Efficacy of iodine-131 6 beta-methyl-iodo-19-norcholesterol scintigraphy and computed tomography in patients with primary aldosteronism.European Journal of Nuclear Medicine1999;26:1326-1332.

• Flood SM, Randolph JF, Gelzer ARM, Refsal K. Primary hyperaldosteronism in two cats.Journal of the American Animal Hospital Association1999;35:411-146.

• Winship SM, Winstanley JHR, Hunter JM. Anaesthesia for Conn’s syndrome.Anaesthesia1999;54:569-574.

• Shen WT, Lim RC, Siperstein AE, Clark OH, Schecter WP, Hunt TK, Horn JK, Duh QY. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism.Archives of Surgery1999;134:628-631.

• Blumenfeld JD, Vaughan ED. Diagnosis and treatment of primary aldosteronism.World Journal of Urology1999;17:15-21.

• Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G. Cardiovascular complications in patients with primary aldosteronism.American Journal of Kidney Diseases1999;33:261-266.

• Proye CAG, Mulliez EAR, Carnaille BML, Lecomte-Houcke M, Decoulx M, Wemeau JL, Lefebvre J, Racadot A, Ernst O, Huglo D, Carre A. Essential hypertension: First reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism?Surgery1998;124:1128-1133.

• Fahmy HI, Melby JC, Mesler DE, Beazley RM, Cho SI, Idelson BA. Primary hyperaldosteronism causing posttransplantation hypertension: Localization by adrenal vein sampling.American Journal of Kidney Diseases1998;31:853-855.

• Siren J, Valimaki M, Huikuri K, Sivula A, Voutilainen P, Haapiainen R. Adrenalectomy for primary aldosteronism: Long-term follow-up study in 29 patients.World Journal of Surgery1998;22:418-422.

• Young WF. Pheochromocytoma and primary aldosteronism: Diagnostic approaches.Endocrinology and Metabolism Clinics of North America1997;26:801.

• Young WF. Primary aldosteronism: Update on diagnosis and treatment.Endocrinologist1997;7:213-221.

E3–E.Yıldırım,O.Çelen, U.Berberoğlu. The Turkish experience with curative gastrectomies for gastric carcinoma: Is D2 dissection worthwhile?Journal of the American College of Surgeons2001,192:25-37.

• TAH El-Fayoumi, HM Fyed, ME Mesiry et al. The applicability of D2 gastrectomy in operable gastric cancer patients: A trial of Alexandria Surgical Oncology UnitAlexandria J Medicine2013; 49(3):229-234.

• WH Allum,JM Blazeby, SM Griffin, D Cunningham et al. Guidelines for the management of oesophageal and gastric cancer.Gut2011;60: 1449-1472.

• MA Memon, MS Subramanya,S Khanet al. Meta-Analysis of D1 Versus D2 Gastrectomy for Gastric AdenocarcinomaAnnals of Surgery2011;253(5):900-911.

• M Scatizzi, KC Kröning, E Lenzi et al. Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer: a case–control study.Updates in Surgery2011;63: 17-23.

• SS Yoon, HK Yang. Lymphadenectomy for Gastric Adenocarcinoma: Should West Meet East?The oncologist2009;14:871-882.

• H Derici, I Yaman, T Tansug, O Nazli, et al. Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma.Gastroenterology Research2009;2(6):317-323.

• S Yalcin. Gastric Cancer in Turkey—A Bridge Between West and East.Gastrointestinal cancer research2009;3(1):29-32.

• Ozmen MM, Ozmen F, Zulfikaroglu.Lymph Nodes in Gastric Cancer
  Journal of Surgical Oncology 2008;98(6):476-481.
• Leong CN, Chung HT, Lee KM, et al. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.Cancer Journal2008;14:269-275.

• Park JM, Kim JH, Park SS, et al.Prognostic factors and availability of D2 lymph node dissection for the patients with stage II gastric cancer: Comparative analysis of subgroups in stage II.World Journal of Surgery2008;32:1037-1044.

• Sasagawa T, Solano H, Vega W, Mena F. The effectiveness of extended lymph node dissection for gastric cancer performed in Costa Rica under supervision of a Japanese surgeon: A comparison with surgical results in Japan.American Journal of Surgery2008;195:53-60.

• Kim MC, Jung GJ, Kim HH.Morbidity and mortality of laparoscopy-assisted gastrectomy with extraperigastric lymph node dissection for gastric cancer.Digestive Diseases And Sciences2007;52: 543-548.

• Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy.European Urology2007;52: 29-37,

• Huscher CGS, Mingoli A, Sgarzini G, et al.Totally laparoscopic total and subtotal gastrectomy with extended lymph node dissection for early long-term results and advanced gastric cancer: early and of a 100-patient series.American Journal of Surgery2007;194: 839-844.

• Wyler SF, Sulser T, Seifert HH, et al. Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer.Urology2006;68:883-887,

• Burkhard FC, Schumaher M, Thalman GN, Studer UE. Is pelvic lymphadenectomy really necessary in patients with a serum prostate-specific antigen level of < 10 ng/ml undergoing radical prostatectomy for prostate cancer?BJU International2005;95(3)275-278.

• Torres JE, Tsoulfas G, Hamdy K, Scott-Conner CEH. Laparoscopic surgery for the prevention, palliation and cure of gastrointestinal malignancies.Medical Clinics of North America2005;89(1):187-.

• Huscher CG, Mingoli A, Sgarzini G, et al. Videolaparoscopic total and subtotal gastrectomy with extended lymph node dissection for gastric cancer.American Journal of Surgery2004;188(6):728-733.

• Shimoyama S, Mafune K, Kaminishi M. Indications for a pylorus-preseving gastrectomy for gastric cancer with proper muscle invasion.Archives of Surgery2003;138:1235-1239.

• Bostancı EB, Yol S, Kayaalp C, Özoğul Y, Atdın C, Atalay F, Akoğlu M. Comparison of complications after D2 and D3 dissection for gastric cancer.European Journal of Surgical Oncology2004,30:20-25.

• Bass BL.What’s new in general surgery: Gastrointestinal conditions.Journal of the American College of Surgeons2002;195:835-54.

• Kasakura Y, Mochizuki F, Wakabayashi K, Kochi M, Fujii M, Takayama T. An evaluation of the effectiveness of extended lymph node dissection in patients with gastric cancer: A retrospective study of 1403 cases at a single institution.Journal of Surgical Research2002;103:252-259.

• Spanknebel KA, Brennan MF. Is D2 lymphadenectomy for gastric cancer a staging tool or a therapeutic intervention?Surgical Oncology Clinics Of North America2002;11:415-430.

E4–H.Altınyollar, U.Berberoğlu,O.Çelen. Lymphatic mapping and sentinel lymph node biopsy in squamous cell carcinoma of the lower lip.European Journal of Surgical Oncology2002;28:72-74.

• AR Schmitt, JD Brewer, JS Bordeaux Staging for Cutaneous Squamous Cell Carcinoma as a Predictor of Sentinel Lymph Node Biopsy Results Meta-analysis of American Joint Committee on Cancer Criteria and a Proposed Alternative SystemJAMA  Dermatol2014;150(1):19-24.

• Guinot JL, Arribas, L, Vendrell JB et al. Prognostic factors in squamous cell lip carcinoma treated with high-dose-rate brachytherapyHead & Neck2014;36(12):1737-1742.

• Allen JE, Stolle LB. Utility of sentinel node biopsy in patients with high-risk cutaneous squamous cell carcinomaEuropean Journal of Surgical Oncology

• Bassi, KK, Srivastava A, Seenu V et al. The First and Second Echelon Sentinel Lymph Node Evaluation in OraCancerIndian Journal of Surgery2013;75: 377-382.

• Vanderlei JPM,Pereira-FilhoFJF , et al. Management of neck metastases in T2N0 lip squamous cell carcinoma.American journal of otolaryngology2013:34(2): 103-106.

• Spratt EAG, Carucci JA. Skin Cancer in Immunosuppressed Patients.Facial Plastic Surgery2013;29: 402-410.

• Gutiérrez‐Pascual, M., et al. Squamous cell carcinoma of the lip. A retrospective study of 146 patients.Journal of the European Academy of Dermatology and Venereology2012;16(9):1116-1121.

• Greenberg JN, Zwald FO. Management of skin cancer in solid-organ transplant recipients: a multidisciplinary approach.Dermatologic clinics2011;29(2): 231-241.

• Kwon S, Dong ZM, Wu PC. Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature.World J Surg Oncol2011;9: 80.

• D Belkin, JA Carucci. Carucci. Mohs surgery for squamous cell carcinoma.Dermatologic clinics2011;29(2): 161-174.

• Guibert M, David I, Vergez S et al. Brachytherapy in lip carcinoma: long-term results.International Journal of Radiation Oncology* Biology* Physics 2011;81(5): e839-e843.

• Xiqiang L, Kolokythas A, Wang J et al. Gene expression signatures of lymph node metastasis in oral cancer: molecular characteristics and clinical significances. Current cancer therapy reviews 2010;6(4): 294.

• MA Kuriakose, NP Trivedi. Sentinel node biopsy in head and neck squamous cell carcinoma. Current opinion in otolaryngology & head and neck surgery 2009;17(2): 100-110.

• Sarper Y, and Ercocen AR. Is Elective Neck Dissection in T1–2, N0 Patients With Lower Lip Cancer Necessary?. Annals of plastic surgery 2009;62: 381-383.

• Civantos F, Zitsch R, Bared A, et al. Sentinel node biopsy for squamous cell carcinoma of the head and neck. Journal of Surgical Oncology 2008;97(8):683-690.

• Reichrath J, Nurnberg. Solar UV-radiation, vitamin D and skin cancer surveillance in organ transplant recipients (OTRs). Sunlight, Vitamin D and Skin Cancer  Book Series: Advances in Experimental Medicine and Biology 2008;624:203-214.

• Morselli P, Masciotra L, Pinto V, et al. Clinical parameters in T1NOMO lower lip squamous cell carcinoma. Journal of Craniofacial Surgery 2007;18(5):1079-1082.

• Civantos F, Zitsch R, Bared A. Sentinel node biopsy in oral squamous cell carcinoma. Journal of Surgical Oncology2007;96(4)330-336.

• Renzi C, Caggiati A, Mannooranparampil TJ, et al. Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: Case series and review of the literatureEJSO 2007;33(3):364-369.

• Martinez JC, Cook JL. High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: Is there a therapeutic role for elective neck dissection? Dermatologıc Surgery 2007;33(4):410-420.

• Devaney KO, Rinaldo A, Rodrigo JP, et al. Sentinel node biopsy and head and neck tumors – Where do we stand today?Head and Neck-Journal for The Sciences And Specialties of The Head and Neck 2006;28(12):1122-1131.

• Ross AS, Schmults CD.Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: A systematic review of the English literature. Dermatologic Surgery 2006;32(11):1309-1321.

• Civantos FJ, Moffat FL, Goodwin WJ. Lymphatic mapping and sentinel lymphadenectomy for 106 head and neck lesions: Contrasts between oral cavity and cutaneous malignancy Laryngoscope  2006;116(3):1-15

• Cecchi R, Buralli L, De Gaudio C. Lymphatic mapping and sentinel lymphadenectomy in recurrent cutaneous squamous cell carcinomas. European Journal of Dermatology2005;15(6):478-479.

• Paleri V, Rees G, Arullenoran P, et al. sentinel lymph node biopsy in squamous cell carcinoma in squamous cell cancer of the oral cavity and oral pharynx: A diagnostic meta-analysis. Head and Neck Journal for the Sciences Specialties of the Head and Neck 2005;27(9):739-747.

• Somma P, Lo Muzio L, Mansueto G, et al. Squamous cell carcinoma of the lower lip: FAS/FASL expression, lymphocyte subtypes and outcome. International Journal of Immunopathology and Pharmacology 2005;18(1):59-64.

• Nouri K, Rivas MP, Pedroso F, et al. Sentinel lymph node biopsy for high risk squamous cell carcinoma of the head and neck. Archives of Dermathology 2004;140(10):1284-1284.

• Carucci JA. Cutaneous oncology in organ transplant recipients: Meeting the challenge of squamous cell carcinoma. Journal of Investigative Dermatology 2004;123(5):809-816.

• Stasko T, Brown MD, Carucci JA, Euvrard S, Johnson TM,Sengelmann RD, Stockfleth E, Tope WD. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatologic Surgery 2004, 30:642-650.

• Vartanian JG, Carvalho AL, de Arajo MJ, Hattori M, Magrin J, Kowalski LP. Predictive factors and distribution of lymph node metastasis in lip cancer patients and their implications on the treatment of the neck. Oral Surgery 2004;40:223-227.

• Carucci JA. Management of squamous cell carcinoma in organ transplant recipients. Seminars in Cutaneous Medicine and Surgery 2003;22:177-186.

• Blazer DG, Sabel MS, Sondak VK. Is there a role for sentinel lymph node biopsy in the management of sarcoma? Surgical Oncology-Oxford 2003;12:201-206.

• Pitman KT, Ferlito A, Devaney KO, Shaha AR, Rinaldo A. Sentinel lymph node biopsy in head and neck cancer. Oral Oncology 2003;39:343-349.

E5- O.Çelen, İ.Kahraman, E.Yıldırım, U.Berberoğlu. “Correlation of vascular endothelial growth factor with clinicopathological variables in colorectal cancer patients”, Neoplasma, 2004;51(4), 293-299.

• Sun, Y. W., et al. Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma. Genet Mol Res 2013;12: 1045-53.
• Sanchez, B. C., et al. Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF. European Journal of Cancer 2010;46: 1580-1587.
• Wang GY, Wang XS, Wang SH, et al. Colorectal cancer progression correlates with upregulation of S100A11 expression in tumor tissues. International Journal of Colorectal Disease 2008;23(7):675-682.

• Li YH, Hu CF, Shao Q, et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. Journal Of Translational Medicine   2008;6(1).

• Famulsiki W, Sulkowska M, Wincewics A, et al. P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. Neoplasma 2006;53(1):43-48.

• Fuckar D, Dekanic A, Stifter S, et al. VEGF expression is associated with negative estrogen receptor status in patient with breast cancer. International Journal of Surgical Pathology 2006; 14(1):49-55.

• Krishna SM, James S, Balaram P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Research 2006; 115(1):85-90.

• Lin JD, Chao TC. Vascular endothelial growth factor in thyroid cancer. Cancer Biotherapy and Radiopharmaceuticals 2005;20(6):648-661.

E6- U.Berberoğlu, E.Yıldırım, O.Çelen. “Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer”, The International Journal of Biological Markers 2004;19(2):130-134.

• Raaschou, Pauline, et al. “TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.” Annals of the rheumatic diseases (2014): annrheumdis-2014.

• da Rocha, Aline Franco, et al. Inhibitory effect of tumor necrosis factor α on gluconeogenesis in perfused rat liver. Molecular and cellular biochemistry 2013;375: 89-96.

• Flores-Ramos, L. Gómez, et al. Association of the tumor necrosis factor-alpha− 308 G> A polymorphism with breast cancer in Mexican women. Genetics and Molecular Research 2013;121(4): 5680-5693.

• To, Sarah Q., Kevin C. Knower, and Colin D. Clyne. Origins and Actions of Tumor Necrosis Factor α in Postmenopausal Breast Cancer. Journal of Interferon & Cytokine Research 2013;33(7): 335-345.

• Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes?
  Acta Pharmacologica Sinica   2008;29(11):1275-1288.

• Grim-Stieger M, Keilani M, Mader RM, et al. Serum levels of tumor necrosis factor-alpha and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate. Preliminary data of Viennese outpatint with metastatic cancer during palliative chemotherapy. European Journal of Cancer Care 2008;17:454-462.

• Fagerholm R, Hofstetter B, Tommiska J, et al. NAD(P)H:Quinone oxidoreductase 1 NOO1 (star) 2 genotype (P187S) is astrong prognostic and predictive factor in breast cancer. Nature Genetics 2008;40:844-853.

• Mills PJ, Ancoli-Israel S, Parker B, et al. Predictors of inflammation in response

to anthracycline-based chemotherapy for breast cancer. Brain Behavior and Immunity 2008;22(1):98-104.

• Premkumar VG, Yuvaraj S, Vijayasarathy K, et al.Serum cytokine levels of interleukin-1 beta,-6,-8,tumor necrosisfactor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. Basic and Clinical Pharmacology and Toxicology 2007;100:387-391.

• Sirotkovic-Skerlev M, Cacev T, Kapitanovic S. Tumor necrosis Factor alpha and breast cancer. Periodicum Biologorum 2006;108:541-546.

• Beresford M, Padhani AR, Goh V, et al. Imaging breast cancer response during neoadjuvant systemic therapy. Expert review of Anticancer Therapy 2005;5:893-905.

E7- O.Çelen, E.Yıldırım, U.Berberoğlu. “Factors influencing outcome of surgery for stage I rectal cancer”, Neoplasma 2004;51(6), 487-490 .

• Uribarrena A, Rafael, et al. Prognostic value of microvascular density in Dukes A and B (T1–T4, N0, M0) colorectal carcinomas.” Gastroenterology research and practice 2009 (2009).

• Uribarrena-Amezaga, R., et al. Prognostic value of lymph node micrometastasis in patients with colorectal cancer in Dukes stages A and B (T1-T4, N0, M0). Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva 2010;102(3): 176-186.

• Ptok H, Meyer F, Steinert R, et al. No prognostic impact of isolated lymphovascular invasion after radical resection of rectal cancer – results of a multicenter observational study International Journal of Colorectal Disease   2007;22(7):749-756.

E8- E. Yıldırım, O. Çelen, K. Gülben and U. Berberoğlu. ”The surgical management of incidental gallbladder carcinoma”,  European Journal of Surgical Oncology 31(1),45-52 (2005).

• Yoon, Jong Hee, et al. “What is the Better Choice for T1b Gallbladder Cancer: Simple Versus Extended Cholecystectomy.” World journal of surgery12 (2014): 3222-3227.

• Kai, Keita, Shinichi Aishima, and Kohji Miyazaki. “Gallbladder cancer: Clinical and pathological approach.” World Journal of Clinical Cases: WJCC10 (2014): 515.

• Gryko, M., et al. “Cancer of the gallbladder–own experience.” Progress in Health Sciences1 (2014): 153-157.

• Salah, Berkane, and Abid Larbi. “Early Gallbladder Cancer: Clinical, Morphological, Therapeutic and Evolutionary Aspects.” Surgical Science11 (2013): 486.

• Behari, Anu, and Vinay K. Kapoor. “Incidental Gall Bladder Cancer.” Advances in surgery1 (2013): 227-249.

• Argon, Asuman, et al. “A Different Perspective on Macroscopic Sampling of Cholecystectomy Specimens.” Korean journal of pathology6 (2013): 519-525.

• Kumar, Rakesh, et al. “Role of 18F-FDG PET/CT in detecting recurrent gallbladder carcinoma.” Clinical nuclear medicine5 (2012): 431-435.

• Mazer, Laura M., et al. “Tumor characteristics and survival analysis of incidental versus suspected gallbladder carcinoma.” Journal of Gastrointestinal Surgery7 (2012): 1311-1317.

• Wang, Jing-Han, et al. “Establishment and characterization of a cell line, EH-GB2, derived from hepatic metastasis of gallbladder cancer.” Oncology reports3 (2012): 775.

• Lee, Seung Eun, et al. “Systematic review on the surgical treatment for T1 gallbladder cancer.” World journal of gastroenterology: WJG2 (2011): 174.

• TÜZÜNER, Acar, Esra ERDEN, and Kaan KARAYALÇIN. “Incidental gallbladder cancer diagnosed during or after laparoscopic cholecystectomy in members of the Turkish population with gallstone disease.” Turk J Gastroenterol5 (2011): 513-516.

• Isambert, M., et al. “Incidentally-discovered gallbladder cancer: When, why and which reoperation?.” Journal of visceral surgery2 (2011): e77-e84.

• Cho, Seong Yeon, et al. “Comparative analysis between clinical outcomes of primary radical resection and second completion radical resection for T2 gallbladder cancer: single-center experience.” World journal of surgery7 (2010): 1572-1578.

• He, Xiao-Dong, et al. “Gender-specific prognostic markers of patients with gallbladder cancer after surgical resection.” The American surgeon11 (2010): 1269-1274.

• Hueman, Matthew T., Charles M. Vollmer Jr, and Timothy M. Pawlik. “Evolving treatment strategies for gallbladder cancer.” Annals of surgical oncology8 (2009): 2101-2115.

• Pilgrim, C., Val Usatoff, and Peter M. Evans. “A review of the surgical strategies for the management of gallbladder carcinoma based on T stage and growth type of the tumour.” European Journal of Surgical Oncology (EJSO)9 (2009): 903-907.

• Choi, Sae Byeol, et al. “Incidental gallbladder cancer diagnosed following laparoscopic cholecystectomy.” World journal of surgery12 (2009): 2657-2663.

• Shibata, Kohei, et al. “Lymphatic invasion: an important prognostic factor for stages T1b–T3 gallbladder cancer and an indication for additional radical resection of incidental gallbladder cancer.” World journal of surgery5 (2009): 1035-1041.

• Reddy, Srinevas K., and Bryan M. Clary. “Surgical management of gallbladder cancer.” Surgical oncology clinics of North America2 (2009): 307-324.

• De Aretxabala, Xabier, et al. “Early gallbladder cancer: is further treatment necessary?.” Journal of surgical oncology7 (2009): 589-593.

• Pilgrim, Charles HC, Val Usatoff, and Peter Evans. “Consideration of anatomical structures relevant to the surgical strategy for managing gallbladder carcinoma.” European Journal of Surgical Oncology (EJSO)11 (2009): 1131-1136.

• Abramson, Michael A., et al. “Radical resection for T1b gallbladder cancer: a decision analysis.” HPB8 (2009): 656-663.

• Yeu, Kyung-jun, et al. “Should the extrahepatic bile duct be resected for T2 gallbladder cancer?.” Journal of the Korean Surgical Society2 (2009): 113-119.

• Gourgiotis S, Kocher HM, Solaini L, et al. Gallbladder cancer. American Journal of Surgery 2008;96:252-264.

• Zulke C, Schlitt HJ. Incidentalomas of the liver and gallbladder – Evaluation and therapeutic procedure Chirurg   2007;78: 698-712.

• Thomas MB.Biological characteristics of cancers in gallbladder and Biliary tract and targeted therapy. Critical Reviews in Oncology Hematology 2007;61:44-51.

• Reid KM, Ramos-De la Medina A, Donohue JH.Diagnosis and surgical management of gallbladder cancer: A review.
  Journal of Gastroıntestınal Surgery 2007;11: 671-681.

• Shirai Y, Wakai T, Hatakeyama K.Radical lymph node dissection for gallbladder cancer: Indications and limitations.Surgical Oncology Clinics of North America2007;16: 221-+.

• Steinert R, Nestler G, Sagynaliev E, et al. Laparoscopic cholecystectomy and gallbladder cancer. Journal of Surgical Oncology 2006;93:682-689.

• Misra MC, Gulera S. Management of cancer gallbladder found as a surprise on a resected gallbladder specimen. Journal of Surgical Oncology 2006;93:690-698.

E9- O. Çelen, E Yıldırım, N Özen, C Sonmez. “Predictive value of relative changes in serum total sialic acid level for response to neoadjuvant chemotherapy in patients with locally advanced breast” carcinoma. Neoplasma 2006;53,347-51.

• Fleitas, T., et al. “VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.” Clinical and Translational Oncology11 (2013): 897-902.
• Reynés, Gaspar, et al. “Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma.” Journal of neuro-oncology1 (2011): 35-41.

• Gökmen, Selma S., et al. “Küçük Hücreli Dışı Akciğer Kanserli Hastalarda Sisplatin+ Etoposid Tedavisinin Serum Total ve Lipide Bağlı Sialik Asid Düzeylerine Etkisi.” Türk Biyokimya Dergisi3 (2010): 236.

• Gokmen SS, Kazezoglu C, Tabakoglu E, et al. The importance of serum total and lipid-bound sialic acid as markers in patients with small cell and non-small cell lung carcinoma Trakya Ünıversitesi Tıp Fakultesi Dergisi 2007;24(2):101-108

E10- O.Çelen, E.Yıldırım, U.Berberoğlu. “Prognostıc impact of positive lymph node ratio in gastric carcinoma”, Journal of Surgical oncology 2007;96(2):95-101 .

• Smith, David D., Rebecca A. Nelson, and Roderich E. Schwarz. “A Comparison of Five Competing Lymph Node Staging Schemes in a Cohort of Resectable Gastric Cancer Patients.” Annals of surgical oncology3 (2014): 875-882.

• Rosa, Fausto, et al. “Lymph node ratio for gastric cancer: useful instrument or just an expedient to retrieve fewer lymph nodes?.” Annals of surgery4 (2014): e65.

• Ryu, In Sun, et al. “Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma.” Annals of surgical oncology1 (2014): 277-283.

• Aurello, Paolo, et al. “Log Odds of Positive Lymph Nodes (LODDS): What Are Their Role in the Prognostic Assessment of Gastric Adenocarcinoma?.” Journal of Gastrointestinal Surgery (2014): 1-7

• Zhang, Bao-yan, et al. “Evaluation of the prognostic value of the metastatic lymph node ratio for gastric cancer.” The American Journal of Surgery4 (2014): 555-565.

• Lin, Dapeng, et al. “Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes.” American journal of clinical oncology4 (2013): 325-330.

• Xu, Jia, et al. “Prognostic assessment of different metastatic lymph node staging methods for gastric cancer after D2 resection.” World journal of gastroenterology: WJG12 (2013): 1975.

• Wang, Jiping, et al. “Comparison of a lymph node ratio–based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database.” Annals of surgery3 (2012): 478-485.

• Lee, Sung Ryol, et al. “Prognostic significance of the metastatic lymph node ratio in patients with gastric cancer.” World journal of surgery5 (2012): 1096-1101.

• Lang, Brian Hung-Hin, et al. “Significance of metastatic lymph node ratio on stimulated thyroglobulin levels in papillary thyroid carcinoma after prophylactic unilateral central neck dissection.” Annals of surgical oncology4 (2012): 1257-1263.

• Deng, Jingyu, et al. “Clinicopathologic characteristics and outcomes of surgery of middle-third gastric cancer.” Tumor Biology6 (2012): 2091-2098.

• Wang, W., et al. “Tumor–ratio–metastasis staging system as an alternative to the 7th edition UICC TNM system in gastric cancer after D2 resection—results of a single-institution study of 1343 Chinese patients.” Annals of oncology (2011): mdq716.

• Xiao, Long-Bin, et al. “Superiority of metastatic lymph node ratio to the 7th edition UICC N staging in gastric cancer.” World journal of gastroenterology: WJG46 (2011): 5123.

• Petrelli, F., K. Borgonovo, and S. Barni. “The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature.” European Journal of Surgical Oncology (EJSO)10 (2011): 836-847.

• Wenguang, Wu, et al. “Three-step method for lymphadenectomy in gastric cancer surgery: a single institution experience of 120 patients.” Journal of the American College of Surgeons2 (2011): 200-208.

• Jacomo, Alfredo Luiz, et al. “Prognostic impact of the lymph node metastatic ratio on 5-year survival of patients with rectal cancer not submitted to preoperative chemoradiation.” Journal of Coloproctology (Rio de Janeiro)4 (2011): 311-324.

• Sun, Zhe, et al. “Log odds of positive lymph nodes.” Cancer11 (2010): 2571-2580.

• Lee, So-Young, et al. “Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes?.” International journal of oncology6 (2010): 1461-1467.

• Maduekwe, Ugwuji N., et al. “New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma.” Annals of surgical oncology5 (2010): 1267-1277.

• Bilici, Ahmet, et al. “Determining of metastatic lymph node ratio in patients who underwent D2 dissection for gastric cancer.” Medical Oncology3 (2010): 975-984.

• Pedrazzani, Corrado, et al. “Ratio between metastatic and examined lymph nodes (N ratio) may have low clinical utility in gastric cancer patients treated by limited lymphadenectomy: results from a single-center experience of 526 patients.” World journal of surgery1 (2010): 85-91.

• Kim, Jin-Soo, et al. “Increasing nodal ratio is a poor prognostic factor for survival in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant chemotherapy: a retrospective study.” Japanese journal of clinical oncology (2010): hyq215.

• Xu, Da-zhi, et al. “Positive lymph node ratio is an independent prognostic factor in gastric cancer after d2 resection regardless of the examined number of lymph nodes.” Annals of surgical oncology2 (2009): 319-326.

• Sun, Z., et al. “The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: results from a Chinese mono-institutional study in 2159 patients.” Annals of oncology (2009): mdn707.

• Macdonald, O. Kenneth, et al. “Prognostic significance of histology and positive lymph node involvement following radical hysterectomy in carcinoma of the cervix.” American journal of clinical oncology4 (2009): 411-416.

• Priolli, D. G., et al. “Metastatic lymph node ratio as an independent prognostic variable in colorectal cancer: study of 113 patients.” Techniques in coloproctology2 (2009): 113-121.

• Kim, Chan-Young, and Doo-Hyun Yang. “Adjustment of N stages of gastric cancer by the ratio between the metastatic and examined lymph nodes.” Annals of surgical oncology7 (2009): 1868-1874.

• Persiani, Roberto, et al. “Metastatic lymph node ratio: a new staging system for gastric cancer.” World journal of surgery10 (2009): 2106-2111.

• Wang, Xi, et al. “Prognostic value of the ratio of metastatic lymph nodes in gastric cancer: an analysis based on a Chinese population.” Journal of surgical oncology6 (2009): 329-334.

• Hagen, Jeffrey A. “Revisions in the Staging System for Esophageal.” Esophageal Cancer: Principles and Practice (2009): 209.

• Huang CM, Lin BJ, Lu HS, et al. Prognostic impact of metastatic lymph node ratio in advanced gastric cancer from cardia and fundus. World Journal of Surgery 2008;14:4383-4388.

• Nitti D, Mocellin S, Marchet A, et al. Recent advances in conventional and molecular prognostic factors for gastric carcinoma. Surgical Oncology Clinics of North America   2008;17: 467-+.

• Wang X, Wang JJ, Wan F. A common misuse of stepwise regression in studies of ratio of metastatic lymph nodes for gastric cancer. Annals of Surgical Oncology   2008;15: 1805-1806.

• Zheng HC, Tsuneyama K, Takahashi H, et al. Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. Journal of Cancer Research and Clinical Oncology 2008;134: 481-488.

E11- K. Gülben, U. Berberoğlu, O. Çelen, H.H.Mersin. “Incidental papillary microcarcinoma of the thyroid-factors affecting lymph node metastasis”, Langenbecks Archives of Surgery 2008;333(1):25-29.

• Mehanna, Hisham, et al. “Differences in the Recurrence and Mortality Outcomes Rates of Incidental and Nonincidental Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-Analysis of 21 329 Person-Years of Follow-Up.” The Journal of Clinical Endocrinology & Metabolism (2014).

• Brito, Juan P., Ian D. Hay, and John C. Morris. “Low risk papillary thyroid cancer.” BMJ 348 (2014).

• Girardi, Fábio Muradás, Marinez Bizarro Barra, and Cláudio Galleano Zettler. “Predictive Factors for Lymph Node Metastasis in Solitary Papillary Thyroid Carcinomas: A Retrospective Study.” Pathology & Oncology Research (2014): 1-6.

• Vinagre, João, et al. “Differentiated thyroid cancer in patients with resistance to thyroid hormone syndrome. A novel case and a review of the literature.” Molecular Diagnostics 1 (2014): 10.

• Nakamura, Masanori, et al. “E‑cadherin expression and cell proliferation in the primary tumor and metastatic lymph nodes of papillary thyroid microcarcinoma.” Molecular and clinical oncology2 (2014): 226-232.

• Varshney, R., et al. “Lymph node metastasis in thyroid papillary microcarcinoma: a study of 170 patients.” The Journal of Laryngology & Otology10 (2014): 922-925.

• Yang, Yinlong, et al. “Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma.” Clinical endocrinology (2014).

• Ardito, Guglielmo, et al. “Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy.” Clinical nuclear medicine1 (2013): 25-28.

• Zhao, Qunzi, et al. “Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma.” Annals of surgical oncology3 (2013): 746-752.

• Konturek, Aleksander, et al. “Prognostic factors in differentiated thyroid cancer—a 20-year surgical outcome study.” Langenbeck’s Archives of Surgery5 (2012): 809-815.

• Jee, Ye Seob. “First experiences with laparoscopic assisted distal gastrectomy: in the view of comparison with high volume centers.” Journal of the Korean Surgical Society3 (2012): 130-134.

• Tanriover, Ozlem, et al. “Occult papillary thyroid carcinoma: prevalence at autopsy in Turkish people.” European Journal of Cancer Prevention4 (2011): 308-312.

• Kamer, Erdinç, et al. “Tiroidin rastlantısal papiller mikrokarsinomları.” Journal of Dialog in Endocrinology/Endokrinolide Diyalog Dergisi3 (2011).

• Sakorafas, George H., Dimitrios Sampanis, and Michael Safioleas. “Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties.” Surgical oncology2 (2010): e57-e70.

• Zafon, Carles, et al. “Differences in the form of presentation between papillary microcarcinomas and papillary carcinomas of larger size.” Journal of thyroid research 2011 (2010).

• Gelmini, Roberta, et al. “Incidental thyroid carcinoma (ITC): a retrospective study in a series of 737 patients treated for benign disease.” Ann Ital Chir6 (2010): 421-7.

• Lee, Nam Seop, et al. “Risk factors of lymph node metastasis in papillary thyroid microcarcinoma.” Journal of the Korean Surgical Society2 (2010): 82-86.

• Kim, Ju-Yeon, et al. “Clinical characteristics and prognosis of multifocal papillary thyroid carcinoma.” Journal of the Korean Surgical Society6 (2010): 442-446.

• Mercante, Giuseppe, et al. “Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients.” Thyroid7 (2009): 707-716.

• Chung, Yoo Seung, et al. “Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection.” Thyroid3 (2009): 241-246.

• Gül, Kamile, et al. “Comparison of Papillary Thyroid Microcarcinoma and Carcinoma.” Turkish Journal of Endocrinology & Metabolism3 (2009).

• Pakdaman MN, Rochon L, Gologan O, et al.Incidence and histopathological behavior of papillary microcarcinomas: Study of 429 cases. Otolaryngology-Head and Neck Surgery   2008;139:718-722.

• Roh JL, Kim JM, Park. Central cervical nodal metastasis from papillary thyroid microcarcinoma: Pattern and factors predictive of nodal metastasis. Annals of Surgical Oncology   2008;15:2482-2